BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 23039651)

  • 1. Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy.
    Baechler S; Hobbs RF; Boubaker A; Buchegger F; He B; Frey EC; Sgouros G
    Med Phys; 2012 Oct; 39(10):6118-28. PubMed ID: 23039651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of image registration on 3D absorbed dose calculations in
    Grassi E; Fioroni F; Berenato S; Patterson N; Ferri V; Braglia L; Filice A; Versari A; Iori M; Spezi E
    Phys Med; 2018 Jan; 45():177-185. PubMed ID: 29472084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized
    Del Prete M; Buteau FA; Beauregard JM
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1490-1500. PubMed ID: 28361189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant impact of transient deterioration of renal function on dosimetry in PRRT.
    Van Binnebeek S; Baete K; Terwinghe C; Vanbilloen B; Haustermans K; Mortelmans L; Borbath I; Van Cutsem E; Verslype C; Mottaghy FM; Verbruggen A; Deroose CM
    Ann Nucl Med; 2013 Jan; 27(1):74-7. PubMed ID: 22961123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of calculation method on kidney dosimetry in
    Heikkonen J; Mäenpää H; Hippeläinen E; Reijonen V; Tenhunen M
    Acta Oncol; 2016; 55(9-10):1069-1076. PubMed ID: 27219529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized
    Del Prete M; Buteau FA; Arsenault F; Saighi N; Bouchard LO; Beaulieu A; Beauregard JM
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):728-742. PubMed ID: 30506283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations.
    Sarnelli A; Guerriero F; Botta F; Ferrari M; Strigari L; Bodei L; D'Errico V; Grassi E; Fioroni F; Paganelli G; Orecchia R; Cremonesi M
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):216-231. PubMed ID: 26576734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized kidney dosimetry in
    Hou X; Zhao W; Beauregard JM; Celler A
    Phys Med Biol; 2019 Aug; 64(17):175004. PubMed ID: 31456584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dosimetry procedure for organs-at-risk in
    Marin G; Vanderlinden B; Karfis I; Guiot T; Wimana Z; Reynaert N; Vandenberghe S; Flamen P
    Phys Med; 2018 Dec; 56():41-49. PubMed ID: 30527088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects model.
    Hardiansyah D; Riana A; Beer AJ; Glatting G
    Z Med Phys; 2023 Feb; 33(1):70-81. PubMed ID: 35961809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of PET for pretherapeutic prediction of doses in peptide receptor radionuclide therapy.
    Blaickner M; Baum RP
    PET Clin; 2014 Jan; 9(1):99-112. PubMed ID: 25029939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage PRRT with
    Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
    BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival.
    Löser A; Schwarzenböck SM; Heuschkel M; Willenberg HS; Krause BJ; Kurth J
    Nucl Med Commun; 2018 Mar; 39(3):236-246. PubMed ID: 29315138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate.
    Forrer F; Krenning EP; Kooij PP; Bernard BF; Konijnenberg M; Bakker WH; Teunissen JJ; de Jong M; van Lom K; de Herder WW; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2009 Jul; 36(7):1138-46. PubMed ID: 19247653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.
    Garkavij M; Nickel M; Sjögreen-Gleisner K; Ljungberg M; Ohlsson T; Wingårdh K; Strand SE; Tennvall J
    Cancer; 2010 Feb; 116(4 Suppl):1084-92. PubMed ID: 20127957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods.
    Belli ML; Mezzenga E; Di Iorio V; Celli M; Caroli P; Canali E; Matteucci F; Tardelli E; Grassi I; Sansovini M; Nicolini S; Severi S; Cremonesi M; Ferrari M; Paganelli G; Sarnelli A
    J Vis Exp; 2020 Apr; (158):. PubMed ID: 32391816
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Menda Y; Madsen MT; O'Dorisio TM; Sunderland JJ; Watkins GL; Dillon JS; Mott SL; Schultz MK; Zamba GKD; Bushnell DL; O'Dorisio MS
    J Nucl Med; 2018 Nov; 59(11):1692-1698. PubMed ID: 29523629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.
    Sandström M; Garske-Román U; Granberg D; Johansson S; Widström C; Eriksson B; Sundin A; Lundqvist H; Lubberink M
    J Nucl Med; 2013 Jan; 54(1):33-41. PubMed ID: 23223392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kidney dosimetry during
    Sandström M; Garske-Román U; Johansson S; Granberg D; Sundin A; Freedman N
    Acta Oncol; 2018 Apr; 57(4):516-521. PubMed ID: 28920501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.